Epidermolysis bullosa acquisita (EBA) is a chronic mucocutaneous autoimmune skin blistering disease. The current treatment of EBA relies on general immuno suppressive therapy, which does not lead to remission in all cases. Therefore, there is a high unmet medical need for the development of novel therapeutic options. Epidermolysis bullosa acquisita is a rare disorder that causes the skin to blister in response to minor injury.Common areas of blistering include the hands, feet, knees, elbows, and buttocks.
It can also affect the mouth, nose, and eyes. Collagen type VII, the major component of the anchoring fibrils, is the target antigen of this autoimmune disorder. A various novel in vitro and in vivo models of EBA have been established which demonstrates a critical role of the genetic background, T cells, and cytokines for mediating the loss of tolerance towards Collagen type VII.…
